IL146479A0 - Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 - Google Patents

Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35

Info

Publication number: IL146479A0
Authority: IL; Israel
Prior art keywords: adenovirus; serotypes; tropism; proteins; gene delivery
Prior art date: 1999-05-17

Application number

IL14647988A

Other languages

English (en)

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-17

Filing date

2000-05-16

Publication date

2002-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146479(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-16 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2002-07-25 Publication of IL146479A0 publication Critical patent/IL146479A0/xx

Links

241000701161 unidentified adenovirus Species 0.000 title abstract 6
238000001476 gene delivery Methods 0.000 title 1
108090000565 Capsid Proteins Proteins 0.000 abstract 3
102100023321 Ceruloplasmin Human genes 0.000 abstract 3
230000010415 tropism Effects 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
101710145505 Fiber protein Proteins 0.000 abstract 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 abstract 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
210000004072 lung Anatomy 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
230000000241 respiratory effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Virology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL14647988A 1999-05-17 2000-05-16 Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 IL146479A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99201545		1999-05-17
PCT/NL2000/000325 WO2000070071A1 (en)	1999-05-17	2000-05-16	Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35

Publications (1)

Publication Number	Publication Date
IL146479A0 true IL146479A0 (en)	2002-07-25

Family

ID=8240209

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL14647988A IL146479A0 (en)	1999-05-17	2000-05-16	Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
IL146479A IL146479A (en)	1999-05-17	2001-11-13	Adenovirus gene carriers that contain at least one component of type 35 adenovirus
IL214413A IL214413A (en)	1999-05-17	2011-08-02	Human Recombinant Human Adenovirus Type 35, Nucleic Acid Encoded, Nucleic Acid Cell and Method

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL146479A IL146479A (en)	1999-05-17	2001-11-13	Adenovirus gene carriers that contain at least one component of type 35 adenovirus
IL214413A IL214413A (en)	1999-05-17	2011-08-02	Human Recombinant Human Adenovirus Type 35, Nucleic Acid Encoded, Nucleic Acid Cell and Method

Country Status (14)

Country	Link
EP (6)	EP1816205B1 (xx)
JP (2)	JP4843145B2 (xx)
KR (1)	KR100741247B1 (xx)
AT (6)	ATE364707T1 (xx)
AU (1)	AU777041B2 (xx)
CA (1)	CA2372655C (xx)
CY (4)	CY1106762T1 (xx)
DE (4)	DE60045138D1 (xx)
DK (6)	DK1681353T3 (xx)
ES (5)	ES2372824T3 (xx)
IL (3)	IL146479A0 (xx)
NZ (1)	NZ515582A (xx)
PT (5)	PT1816205E (xx)
WO (1)	WO2000070071A1 (xx)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2333425T5 (es)	1995-06-15	2012-08-28	Crucell Holland B.V.	Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US20030017138A1 (en)	1998-07-08	2003-01-23	Menzo Havenga	Chimeric adenoviruses
US6929946B1 (en)	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en)	1999-03-04	2005-03-22	Crucell Holland B.V.	Means and methods for fibroblast-like or macrophage-like cell transduction
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
US6492169B1 (en)	1999-05-18	2002-12-10	Crucell Holland, B.V.	Complementing cell lines
US7094398B1 (en)	1999-06-01	2006-08-22	University Of Washington	Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en)	1999-11-23	2003-05-06	Stefan Kochanek	Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (en) *	2000-09-25	2002-03-27	Galapagos Genomics B.V.	Gene delivery vectors provided with a tissue tropism for T-lymphocytes
AU2001263689B2 (en)	2000-05-31	2007-03-22	University Of Saskatchewan	Modified bovine adenovirus having altered tropism
US20040033605A1 (en) *	2000-09-20	2004-02-19	Menzo Havenga	Gene delivery vectors provided with a tissue tropism for dendritic cells
DE60138403D1 (de)	2000-09-26	2009-05-28	Crucell Holland Bv	Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1195440A1 (en) *	2000-10-06	2002-04-10	Introgene B.V.	Gene delivery vectors for stem cells
WO2002029073A2 (en) *	2000-10-06	2002-04-11	Crucell Holland B.V.	Gene delivery vectors for stem cells
US7459153B2 (en)	2001-01-04	2008-12-02	Wadell Goeran	Viral vectors for gene therapy
US7109029B2 (en)	2001-02-23	2006-09-19	Cell Genesys, Inc.	Vector constructs
AU2003210661A1 (en) *	2002-01-24	2003-09-02	Novartis Ag	Fiber shaft modifications for efficient targeting
ES2310247T3 (es)	2002-04-25	2009-01-01	Crucell Holland B.V.	Vectores adenovirales estables y metodos de propagacion de los mismos.
SI1497438T1 (sl) *	2002-04-25	2010-03-31	Crucell Holland Bv	Sredstva in postopki za pripravo adenovirusnih vektorjev
JP4237449B2 (ja) *	2002-06-05	2009-03-11	国立医薬品食品衛生研究所長	アデノウィルスベクター
US20080153083A1 (en)	2003-10-23	2008-06-26	Crucell Holland B.V.	Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en)	2002-10-23	2005-07-20	Crucell Holland B.V.	New settings for recombinant adenoviral-based vaccines
SG156535A1 (en)	2002-12-17	2009-11-26	Crucell Holland Bv	Recombinant viral-based malaria vaccines
CN1934253A (zh) *	2003-07-18	2007-03-21	昂尼克斯药物公司	用于治疗疾病的b亚组腺病毒载体
AU2005214090B2 (en)	2004-02-23	2008-09-11	Crucell Holland B.V.	Virus purification methods
JP2007532656A (ja) *	2004-04-12	2007-11-15	アメリカ合衆国	アデノウイルスベクターを用いて免疫応答を誘導するための方法
ATE491799T1 (de) *	2004-05-26	2011-01-15	Bayer Schering Pharma Ag	Chimäre adenoviren zur verwendung in der krebsbehandlung
CA2583843C (en)	2004-10-13	2010-09-21	Crucell Holland B.V.	Improved adenoviral vectors and uses thereof
NZ555907A (en)	2004-11-16	2009-12-24	Aeras Global Tb Vaccine Found	Multivalent vaccines comprising recombinant viral vectors
CN101155915B (zh)	2005-04-11	2013-12-04	克鲁塞尔荷兰公司	利用超滤进行病毒纯化
WO2007010028A1 (en)	2005-07-22	2007-01-25	Crucell Holland B.V.	Cell line for producing coronaviruses
WO2007104792A2 (en) *	2006-03-16	2007-09-20	Crucell Holland B.V.	Recombinant adenoviruses based on serotype 26 and 48, and use thereof
ES2532015T3 (es)	2008-11-03	2015-03-23	Crucell Holland B.V.	Método para la producción de vectores adenovíricos
SG178254A1 (en)	2009-08-07	2012-03-29	Transgene Sa	Composition for treating hbv infection
US20120315696A1 (en) *	2010-02-15	2012-12-13	Alfred Luitjens	METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
WO2011098592A1 (en)	2010-02-15	2011-08-18	Crucell Holland B.V.	Method for the production of ad26 adenoviral vectors
US8771709B2 (en)	2010-09-20	2014-07-08	Crucell Holland B.V.	Therapeutic vaccination against active Tuberculosis
US9168292B2 (en)	2010-09-27	2015-10-27	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) *	2011-05-31	2013-10-02	北京锤特生物科技有限公司	溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
CN104379733B (zh)	2012-03-12	2016-01-20	克鲁塞尔荷兰公司	具改变末端的重组腺病毒群
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
MY169352A (en)	2012-03-22	2019-03-25	Janssen Vaccines & Prevention Bv	Vaccine against rsv
US9125870B2 (en)	2012-03-22	2015-09-08	Crucell Holland B.V.	Vaccine against RSV
US9476061B2 (en)	2012-05-24	2016-10-25	Janssen Vaccines & Prevention B.V.	Adenoviral vectors for transduction of vascular tissue
JP6333814B2 (ja)	2012-07-10	2018-05-30	トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅＳ．Ａ．	マイコバクテリア抗原ワクチン
WO2014009433A1 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014078688A2 (en)	2012-11-16	2014-05-22	Beth Israel Deaconess Medical Center, Inc.	Recombinant adenoviruses and use thereof
KR102089121B1 (ko)	2013-03-14	2020-03-13	더 솔크 인스티튜트 포 바이올로지칼 스터디즈	종양살상형 아데노바이러스 조성물
MX361774B (es)	2013-04-25	2018-12-17	Janssen Vaccines & Prevention Bv	Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
PE20160045A1 (es)	2013-06-17	2016-02-18	Crucell Holland Bv	Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
AU2014338864C1 (en)	2013-10-25	2020-07-16	Akamis Bio Limited	Oncolytic adenoviruses armed with heterologous genes
JP6605480B2 (ja)	2014-01-09	2019-11-13	トランスジェン・ソシエテ・アノニム	ヘテロオリゴマーマイコバクテリア抗原の融合物
HRP20240163T1 (hr)	2014-09-03	2024-04-12	Bavarian Nordic A/S	Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
MX2017002890A (es)	2014-09-03	2017-11-13	Bavarian Nordic As	Métodos y composiciones para potenciar respuestas inmunitarias.
PT3197489T (pt)	2014-09-26	2021-04-30	Beth Israel Deaconess Medical Ct Inc	Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
CN107075521B (zh)	2014-11-04	2021-06-08	扬森疫苗与预防公司	治疗性hpv16疫苗
US10570417B2 (en)	2015-04-14	2020-02-25	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
IL284375B (en)	2015-04-30	2022-07-01	Psioxus Therapeutics Ltd	A replication-competent group b oncolytic adenovirus
JP6840718B2 (ja)	2015-07-07	2021-03-10	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	安定化された可溶性融合前ｒｓｖｆポリペプチド
WO2017005844A1 (en)	2015-07-07	2017-01-12	Janssen Vaccines & Prevention B.V.	Vaccine against rsv
EA037295B1 (ru)	2015-08-20	2021-03-05	Янссен Вэксинс Энд Превеншн Б.В.	Терапевтические вакцины против hpv18
CN108368157B (zh)	2015-12-15	2022-04-15	扬森疫苗与预防公司	人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
BR112018012180A2 (pt)	2015-12-17	2018-12-04	Psioxus Therapeutics Ltd	vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
CN117384961A (zh)	2016-02-23	2024-01-12	萨克生物研究学院	对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
EP3390428B1 (en)	2016-02-23	2019-09-25	Salk Institute for Biological Studies	High throughput assay for measuring adenovirus replication kinetics
AU2017248021B2 (en)	2016-04-05	2021-08-12	Janssen Vaccines & Prevention B.V.	Stabilized soluble pre-fusion RSV F proteins
BR112018070323A2 (pt)	2016-04-05	2019-01-29	Janssen Vaccines & Prevention Bv	vacina contra rsv
AU2017259259B2 (en)	2016-05-02	2020-11-19	Bavarian Nordic A/S	Therapeutic HPV vaccine combinations
WO2017207480A1 (en)	2016-05-30	2017-12-07	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
JP6595132B2 (ja)	2016-06-16	2019-10-23	ヤンセンファッシンズアンドプリベンションベーフェー	Ｈｉｖワクチン製剤
US11001858B2 (en)	2016-06-20	2021-05-11	Janssen Vaccines & Prevention B.V.	Potent and balanced bidirectional promoter
WO2018011196A1 (en)	2016-07-14	2018-01-18	Janssen Vaccines & Prevention B.V.	Hpv vaccines
WO2018011768A1 (en)	2016-07-15	2018-01-18	Janssen Vaccines And Prevention B.V.	Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018011198A1 (en)	2016-07-15	2018-01-18	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against a marburg virus infection
GB201713765D0 (en)	2017-08-28	2017-10-11	Psioxus Therapeutics Ltd	Modified adenovirus
CN110062630A (zh)	2016-12-12	2019-07-26	萨克生物研究学院	肿瘤靶向合成腺病毒及其用途
KR102111244B1 (ko)	2017-02-09	2020-05-15	얀센 백신스 앤드 프리벤션 비.브이.	이종 유전자의 발현을 위한 강력한 짧은 프로모터
WO2018185732A1 (en)	2017-04-06	2018-10-11	Janssen Vaccines & Prevention B.V.	Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
WO2018210871A1 (en)	2017-05-17	2018-11-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (en)	2017-05-17	2020-03-25	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
JP7272965B2 (ja)	2017-06-15	2023-05-12	ヤンセンファッシンズアンドプリベンションベーフェー	Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
EP3681533A1 (en)	2017-09-15	2020-07-22	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against rsv
EP3713599A1 (en)	2017-11-20	2020-09-30	Janssen Pharmaceuticals, Inc.	Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
WO2019118480A1 (en)	2017-12-11	2019-06-20	Beth Israel Deaconess Medical Center, Inc.	Recombinant adenoviruses and uses thereof
KR20200100745A (ko)	2017-12-19	2020-08-26	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
BR112021000274A2 (pt)	2018-07-20	2021-04-06	Janssen Vaccines & Prevention B.V.	Vetor adenoviral recombinante expressando antígeno de zika com produtividade melhorada
TW202043256A (zh)	2019-01-10	2020-12-01	美商健生生物科技公司	***新抗原及其用途
CA3140234A1 (en)	2019-05-15	2020-11-19	Janssen Vaccines & Prevention B.V.	Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
US20220273787A1 (en)	2019-05-15	2022-09-01	Janssen Vaccines & Prevention B.V.	Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
AU2020385683A1 (en)	2019-11-18	2022-06-30	Janssen Biotech, Inc.	Vaccines based on mutant CALR and JAK2 and their uses
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
CN111337042B (zh) *	2020-03-13	2021-11-02	湖北大学	一种车辆路径规划方法及***
JP2023521194A (ja)	2020-04-13	2023-05-23	ヤンセンバイオテツク，インコーポレーテツド	Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
US20230024133A1 (en)	2020-07-06	2023-01-26	Janssen Biotech, Inc.	Prostate Neoantigens And Their Uses
US20230035403A1 (en)	2020-07-06	2023-02-02	Janssen Biotech, Inc.	Method For Determining Responsiveness To Prostate Cancer Treatment
EP4175664A2 (en)	2020-07-06	2023-05-10	Janssen Biotech, Inc.	Prostate neoantigens and their uses
WO2022008613A1 (en)	2020-07-08	2022-01-13	Janssen Sciences Ireland Unlimited Company	Rna replicon vaccines against hbv
GB202013940D0 (en)	2020-09-04	2020-10-21	Synpromics Ltd	Regulatory nucleic acid sequences
EP4225382A2 (en)	2020-10-07	2023-08-16	Asklepios Biopharmaceutical, Inc.	Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
WO2022140759A2 (en)	2020-12-23	2022-06-30	Janssen Biotech, Inc.	Neoantigen peptide mimics
WO2023198815A1 (en)	2022-04-14	2023-10-19	Janssen Vaccines & Prevention B.V.	Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2725726B1 (fr) *	1994-10-17	1997-01-03	Centre Nat Rech Scient	Vecteurs viraux et utilisation en therapie genique
US5856152A (en) *	1994-10-28	1999-01-05	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV vector and methods of use therefor
ES2333425T5 (es)	1995-06-15	2012-08-28	Crucell Holland B.V.	Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US5837511A (en) *	1995-10-02	1998-11-17	Cornell Research Foundation, Inc.	Non-group C adenoviral vectors
US5877011A (en) *	1996-11-20	1999-03-02	Genzyme Corporation	Chimeric adenoviral vectors
US6100086A (en) *	1997-04-14	2000-08-08	Genzyme Corporation	Transgene expression systems
WO2000052186A1 (en) *	1999-03-04	2000-09-08	Introgene B.V.	Means and methods for fibroblast-like or macrophage-like cell transduction
AU2009254168A1 (en) *	2008-06-03	2009-12-10	Okairos Ag	A vaccine for the prevention and therapy of HCV infections

2000
- 2000-05-16 EP EP07106054A patent/EP1816205B1/en not_active Expired - Lifetime
- 2000-05-16 PT PT07106054T patent/PT1816205E/pt unknown
- 2000-05-16 EP EP07106036A patent/EP1818408B1/en not_active Expired - Lifetime
- 2000-05-16 KR KR1020017014631A patent/KR100741247B1/ko active IP Right Grant
- 2000-05-16 EP EP05077719A patent/EP1681353B1/en not_active Expired - Lifetime
- 2000-05-16 AU AU49547/00A patent/AU777041B2/en not_active Expired
- 2000-05-16 CA CA2372655A patent/CA2372655C/en not_active Expired - Lifetime
- 2000-05-16 PT PT07106036T patent/PT1818408E/pt unknown
- 2000-05-16 DK DK05077719T patent/DK1681353T3/da active
- 2000-05-16 WO PCT/NL2000/000325 patent/WO2000070071A1/en active Application Filing
- 2000-05-16 ES ES07106054T patent/ES2372824T3/es not_active Expired - Lifetime
- 2000-05-16 EP EP04077434A patent/EP1550722B1/en not_active Expired - Lifetime
- 2000-05-16 JP JP2000618477A patent/JP4843145B2/ja not_active Expired - Lifetime
- 2000-05-16 EP EP07106044A patent/EP1816204B1/en not_active Expired - Lifetime
- 2000-05-16 AT AT04077434T patent/ATE364707T1/de active
- 2000-05-16 DE DE60045138T patent/DE60045138D1/de not_active Expired - Lifetime
- 2000-05-16 DK DK00201738.2T patent/DK1054064T4/da active
- 2000-05-16 ES ES07106044T patent/ES2354578T3/es not_active Expired - Lifetime
- 2000-05-16 AT AT07106036T patent/ATE519855T1/de active
- 2000-05-16 EP EP00201738A patent/EP1054064B2/en not_active Expired - Lifetime
- 2000-05-16 DE DE60035229T patent/DE60035229T2/de not_active Expired - Lifetime
- 2000-05-16 DE DE60014489T patent/DE60014489T3/de not_active Expired - Lifetime
- 2000-05-16 PT PT07106044T patent/PT1816204E/pt unknown
- 2000-05-16 PT PT00201738T patent/PT1054064E/pt unknown
- 2000-05-16 AT AT00201738T patent/ATE278792T1/de active
- 2000-05-16 DK DK07106044.6T patent/DK1816204T3/da active
- 2000-05-16 DE DE60043126T patent/DE60043126D1/de not_active Expired - Lifetime
- 2000-05-16 ES ES07106036T patent/ES2372823T3/es not_active Expired - Lifetime
- 2000-05-16 AT AT07106044T patent/ATE485382T1/de active
- 2000-05-16 ES ES04077434T patent/ES2289426T3/es not_active Expired - Lifetime
- 2000-05-16 IL IL14647988A patent/IL146479A0/xx unknown
- 2000-05-16 NZ NZ515582A patent/NZ515582A/en not_active IP Right Cessation
- 2000-05-16 PT PT04077434T patent/PT1550722E/pt unknown
- 2000-05-16 AT AT07106054T patent/ATE519854T1/de active
- 2000-05-16 AT AT05077719T patent/ATE445018T1/de not_active IP Right Cessation
- 2000-05-16 DK DK04077434T patent/DK1550722T3/da active
- 2000-05-16 ES ES00201738T patent/ES2231103T5/es not_active Expired - Lifetime
- 2000-05-16 DK DK07106054.5T patent/DK1816205T3/da active
- 2000-05-16 DK DK07106036.2T patent/DK1818408T3/da active
2001
- 2001-11-13 IL IL146479A patent/IL146479A/en not_active IP Right Cessation
2007
- 2007-07-25 CY CY20071100996T patent/CY1106762T1/el unknown
2011
- 2011-01-10 CY CY20111100030T patent/CY1111494T1/el unknown
- 2011-07-14 JP JP2011156125A patent/JP5335037B2/ja not_active Expired - Lifetime
- 2011-08-02 IL IL214413A patent/IL214413A/en not_active IP Right Cessation
- 2011-11-07 CY CY20111101075T patent/CY1112189T1/el unknown
- 2011-11-07 CY CY20111101074T patent/CY1112008T1/el unknown

Also Published As

Publication number	Publication date
DK1550722T3 (da)	2007-10-08
NZ515582A (en)	2003-11-28
DK1818408T3 (da)	2011-10-17
DK1681353T3 (da)	2010-01-04
PT1054064E (pt)	2005-02-28
IL214413A0 (en)	2011-09-27
DE60043126D1 (de)	2009-11-19
DK1816205T3 (da)	2011-11-21
DE60014489D1 (de)	2004-11-11
IL214413A (en)	2014-04-30
JP5335037B2 (ja)	2013-11-06
ES2372823T3 (es)	2012-01-26
CA2372655C (en)	2011-11-15
ATE519854T1 (de)	2011-08-15
IL146479A (en)	2011-12-29
ATE278792T1 (de)	2004-10-15
EP1816205A1 (en)	2007-08-08
EP1818408A1 (en)	2007-08-15
ATE519855T1 (de)	2011-08-15
CY1111494T1 (el)	2015-08-05
ES2289426T3 (es)	2008-02-01
CY1112008T1 (el)	2015-11-04
PT1818408E (pt)	2011-11-15
EP1681353B1 (en)	2009-10-07
PT1816205E (pt)	2011-11-15
DK1054064T4 (da)	2010-05-03
ES2231103T3 (es)	2005-05-16
EP1054064B2 (en)	2009-12-16
EP1550722A1 (en)	2005-07-06
ES2372824T3 (es)	2012-01-26
ES2354578T3 (es)	2011-03-16
EP1054064B1 (en)	2004-10-06
KR100741247B1 (ko)	2007-07-19
CA2372655A1 (en)	2000-11-23
CY1106762T1 (el)	2012-05-23
EP1550722B1 (en)	2007-06-13
DE60014489T2 (de)	2005-11-24
JP2011224014A (ja)	2011-11-10
AU777041B2 (en)	2004-09-30
KR20020028879A (ko)	2002-04-17
ATE445018T1 (de)	2009-10-15
ES2231103T5 (es)	2010-04-15
DE60014489T3 (de)	2010-08-12
JP4843145B2 (ja)	2011-12-21
EP1816204A1 (en)	2007-08-08
EP1818408B1 (en)	2011-08-10
EP1054064A1 (en)	2000-11-22
PT1550722E (pt)	2007-09-25
DK1816204T3 (da)	2011-01-24
CY1112189T1 (el)	2015-12-09
PT1816204E (pt)	2011-01-24
ATE485382T1 (de)	2010-11-15
ATE364707T1 (de)	2007-07-15
DE60035229T2 (de)	2008-02-21
EP1816204B1 (en)	2010-10-20
WO2000070071A1 (en)	2000-11-23
JP2002543846A (ja)	2002-12-24
EP1816205B1 (en)	2011-08-10
EP1681353A1 (en)	2006-07-19
DE60035229D1 (de)	2007-07-26
DK1054064T3 (da)	2005-01-10
AU4954700A (en)	2000-12-05
DE60045138D1 (de)	2010-12-02

Publication	Publication Date	Title
IL146479A0 (en)	2002-07-25	Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
WO2002094200A3 (en)	2003-02-20	Pulmonary administration of chemically modified insulin
ATE237694T1 (de)	2003-05-15	Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO2000073478A3 (en)	2001-07-05	Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
HUP0003533A3 (en)	2003-08-28	Interleukin-18 binding proteins, their preparation and use
WO2003099859A3 (de)	2004-04-15	Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1270586A3 (de)	2003-10-15	Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
WO2006086357A3 (en)	2007-02-01	Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
AU2002228805A1 (en)	2002-06-18	Antisense modulation of damage-specific dna binding protein 2, p48 expression
ZA200006309B (en)	2001-10-24	A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
WO2003008449A8 (en)	2004-02-26	Ntb-a, a surface molecule involved in natural killer cells activity
AU3479699A (en)	1999-10-25	A polypeptide comprising the amino acid of an n-terminal choline binding proteina truncate, vaccine derived therefrom and uses thereof
EP1593742A3 (en)	2006-02-01	Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
WO1998052617A3 (en)	1999-08-12	Contrast media for imaging of lung draining lymph nodes, administered through the lungs
WO2002083902A3 (en)	2003-08-14	Adenovirus serotype 30 (ad30) fiber protein and uses thereof
WO2002083896A3 (en)	2003-03-13	Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
WO2001079473A3 (en)	2002-04-25	21953, a human prolyl oligopeptidase family member and uses thereof
WO2002081514A3 (en)	2003-03-13	A novel f-box protein
WO2001081607A3 (en)	2002-06-13	Adenovirus vectors with knobless fibers, and their uses
WO2001077293A3 (en)	2002-03-14	Gp40 and uses thereof
WO2002052020A3 (en)	2003-09-04	Regulation of human carboxypeptidase a